Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2023-11-17 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
第四届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 10th meeting of the 4th Board of Directors of Betta Pharmaceuticals Co., Ltd. It includes information about the meeting's convening, attendance, and voting results on various proposals such as the 2023 restricted stock incentive plan, amendments to the company charter, and other governance-related matters. The document does not contain financial statements or quarterly/yearly financial results but focuses on board decisions and governance issues. It is not a full annual or interim report, nor an earnings release or audit report. It is not a simple announcement of a report publication but a substantive board meeting resolution document. Therefore, it fits best under the category of Board/Management Information (MANG). The document length (6220 characters) and content support this classification with high confidence.
2023-11-17 Chinese
2023年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as the "2023 年限制性股票激励计划实施考核管理办法" which translates to "2023 Restricted Stock Incentive Plan Implementation Assessment Management Measures". It details the management, assessment criteria, and procedures related to a restricted stock incentive plan for company directors, senior management, and key personnel. The content focuses on performance evaluation, stock vesting conditions, and governance of the incentive plan. There is no indication that this is a financial report, earnings release, or regulatory filing about financial results. It is not a proxy solicitation or voting results announcement, nor is it a remuneration report specifically detailing compensation amounts. Instead, it is a governance-related document outlining internal rules and procedures for stock incentives. Therefore, the most appropriate classification is Governance Information (CGR). The document length is about 4952 characters, which is substantive and contains detailed policy content, not a brief announcement or certification, so it is not RPA or RNS.
2023-11-17 Chinese
2023年限制性股票激励计划（草案）摘要
Remuneration Information Classification · 95% confidence The document is a detailed draft of a 2023 restricted stock incentive plan by 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It includes comprehensive information about the stock incentive plan, such as legal basis, stock source, quantity, allocation, eligibility criteria, performance targets, management structure, and implementation procedures. The document references relevant laws and regulations, detailed terms of the incentive plan, and includes extensive tables and explanations. It is not a brief announcement or a simple notice but a full plan document. This type of document is related to executive and employee compensation and stock incentive plans, which falls under Remuneration Information filings. It is not an Annual Report, Earnings Release, or Board/Management change announcement. It is not a Proxy Solicitation or Voting Results announcement either. Therefore, the best fitting category is Remuneration Information (DEF 14A). The document length (15,000 characters) and content confirm it is a full plan document, not just an announcement or summary.
2023-11-17 Chinese
关于使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 贝达药业股份有限公司 regarding the use of part of idle raised funds to temporarily supplement working capital. It details board and supervisory meetings approving the use of idle raised funds, references regulatory approvals from the China Securities Regulatory Commission, and discusses the amounts and terms of fund usage. The document is a formal public announcement about the company's financing and capital management activities, specifically the use of raised funds. It does not contain full financial statements or comprehensive financial performance data, nor is it a transcript or presentation. It is not a report publication announcement since it contains substantive information about the use of funds and approvals. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-11-17 Chinese
监事会关于公司2023年限制性股票激励计划相关事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion on the company's 2023 restricted stock incentive plan. It discusses compliance with laws and regulations, qualifications of incentive recipients, and governance aspects related to the stock incentive plan. It is not a financial report, earnings release, or management discussion. It is an official announcement related to corporate governance and incentive plan approval, but it does not announce voting results or changes in board members. It is not a proxy solicitation or remuneration report. The document is a regulatory announcement about the stock incentive plan and related compliance, fitting best under Regulatory Filings (RNS). The document length is short (1970 characters), and it contains detailed verification opinions rather than just a notice of report publication, so it is not RPA. Therefore, the best classification is Regulatory Filings (RNS).
2023-11-17 Chinese
创业板上市公司股权激励计划自查表
Governance Information Classification · 95% confidence The document is a detailed compliance self-inspection checklist related to a stock incentive plan for a listed company (贝达药业). It includes numerous compliance checks, legal and financial advisor opinions, and procedural confirmations related to the stock incentive plan. There is no indication that this is a full financial report, audit report, or earnings release. It is not a brief announcement or a presentation but a compliance and governance-related document focused on stock incentive plans. This fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices, including stock incentive plans and related compliance.
2023-11-17 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.